drugset / Trial / NCT04226105
Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T2DM comparing the efficacy and safety of GP40081 (insulin asapart mix 30, GEROPHARM) with that of NovoMix® 30 FlexPen®.
Timeline
- Start
- 2020-01-20
- Primary completion
- 2020-09-30
- Completion
- 2020-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | biphasic insulin aspart | Protein / enzyme biologic | — | Subcutaneous |
| Subject | biphasic insulin aspart 30 | Protein / enzyme biologic | — | Subcutaneous |